Clovis Oncology Inc.
| NASDAQ: CLVS | Healthcare / Biotechnology / USA |
| 5.77 | -0.0700 | -1.20% | Vol 5.88M | 1Y Perf -19.37% |
| Jun 15th, 2021 16:00 DELAYED |
| BID | 5.77 | ASK | 5.79 | ||
| Open | 5.85 | Previous Close | 5.84 | ||
| Pre-Market | - | After-Market | 5.80 | ||
| - - | 0.03 0.52% |
| Target Price | 6.69 | Analyst Rating | Hold 3.14 | |
| Potential % | 15.94 | Finscreener Ranking | ★★★+ — - | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★★ — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Market Cap | 603.34M | Earnings Rating | Strong Buy | |
| Price Range Ratio 52W % | 24.07 | Earnings Date | 5th Aug 2021 |
Today's Price Range 5.716.14 | 52W Range 4.0811.10 | 5 Year PE Ratio Range -4.40-1.60 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -8.56% | ||
| 1 Month | -1.70% | ||
| 3 Months | 2.85% | ||
| 6 Months | 14.26% | ||
| 1 Year | -19.37% | ||
| 3 Years | -87.34% | ||
| 5 Years | -58.10% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -459.11 | |||
ROE last 12 Months | 188.78 | |||
ROA (5Y Avg) | -63.11 | |||
ROA last 12 Months | -56.55 | |||
ROC (5Y Avg) | -62.87 | |||
ROC last 12 Months | -18.45 | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | -52.17 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 5.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.60 | ||||
| 7.70 | ||||
| 3.82 | ||||
| - | ||||
| -2.50 | ||||
| -2.51 | ||||
| -1.73 | ||||
| -2.11 | ||||
| 1.08B | ||||
| Forward PE | -4.44 | |||
| PEG | -0.03 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.30 | ||||
| 1.50 | ||||
| - | ||||
| - | ||||
| -12.10 | ||||
| Leverage Ratio | -3.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 74.60 | ||||
| -194.40 | ||||
| -189.20 | ||||
| -98 040.00 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 160.01M | ||||
| 1.53 | ||||
| 30.65 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2021 | -0.72 | -0.64 | 11.11 |
| Q04 2020 | -0.76 | -0.74 | 2.63 |
| Q03 2020 | -1.01 | -0.89 | 11.88 |
| Q02 2020 | -1.02 | -1.11 | -8.82 |
| Q01 2020 | -1.29 | -1.28 | 0.78 |
| Q04 2019 | -1.61 | -1.81 | -12.42 |
| Q03 2019 | -1.92 | -1.89 | 1.56 |
| Q02 2019 | -1.70 | -2.27 | -33.53 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2021 QR | -0.57 | 8.06 | Positive |
| 9/2021 QR | -0.52 | 13.33 | Positive |
| 12/2021 FY | -2.32 | 13.75 | Positive |
| 12/2022 FY | -1.30 | 22.62 | Positive |
| Next Report Date | 5th Aug 2021 |
| Estimated EPS Next Report | -0.57 |
| Estimates Count | 5 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 5.88M |
| Shares Outstanding | 104.57M |
| Trades Count | 23.04K |
| Dollar Volume | 74.76M |
| Avg. Volume | 10.24M |
| Avg. Weekly Volume | 16.11M |
| Avg. Monthly Volume | 8.16M |
| Avg. Quarterly Volume | 11.32M |
Clovis Oncology Inc. (NASDAQ: CLVS) stock closed at 5.77 per share at the end of the most recent trading day (a -1.2% change compared to the prior day closing price) with a volume of 5.92M shares and market capitalization of 603.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Clovis Oncology Inc. CEO is Patrick J. Mahaffy.
The one-year performance of Clovis Oncology Inc. stock is -19.37%, while year-to-date (YTD) performance is 20.21%. CLVS stock has a five-year performance of -58.1%. Its 52-week range is between 4.08 and 11.1, which gives CLVS stock a 52-week price range ratio of 24.07%
Clovis Oncology Inc. currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 7.70, a price-to-sale (PS) ratio of 3.82, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -56.55%, a ROC of -18.45% and a ROE of 188.78%. The company’s profit margin is -%, its EBITDA margin is -189.20%, and its revenue ttm is $160.01 Million , which makes it $1.53 revenue per share.
Of the last four earnings reports from Clovis Oncology Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.57 for the next earnings report. Clovis Oncology Inc.’s next earnings report date is 05th Aug 2021.
The consensus rating of Wall Street analysts for Clovis Oncology Inc. is Hold (3.14), with a target price of $6.69, which is +15.94% compared to the current price. The earnings rating for Clovis Oncology Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Clovis Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Clovis Oncology Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.05, ATR14 : 0.43, CCI20 : 81.89, Chaikin Money Flow : -0.44, MACD : 0.05, Money Flow Index : 68.62, ROC : 10.54, RSI : 52.70, STOCH (14,3) : 34.08, STOCH RSI : 0.26, UO : 38.21, Williams %R : -65.92), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Clovis Oncology Inc. in the last 12-months were: Brian G. Atwood (Option Excercise at a value of $21 240), Daniel W. Muehl (Option Excercise at a value of $0), Daniel W. Muehl (Sold 23 339 shares of value $157 380 ), Gillian C. Ivers-Read (Option Excercise at a value of $226 205), Gillian C. Ivers-Read (Sold 22 511 shares of value $153 154 ), Lindsey Rolfe (Option Excercise at a value of $56 550), Lindsey Rolfe (Sold 27 286 shares of value $183 940 ), Paul Edward Gross (Option Excercise at a value of $0), Paul Edward Gross (Sold 23 099 shares of value $156 167 ), Thomas C. Harding (Option Excercise at a value of $0), Thomas C. Harding (Sold 17 828 shares of value $118 098 )
Clovis Oncology Inc.
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.
CEO: Patrick J. Mahaffy
Telephone: +1 303 625-5000
Address: 5500 Flatiron Parkway, Boulder 80301, CO, US
Number of employees: 429
